Literature DB >> 19620313

Perturbation of the CD4 T cell compartment and expansion of regulatory T cells in autoimmune-prone Lyn-deficient mice.

Evelyn Tsantikos1, Cathy Quilici, Kenneth W Harder, Bo Wang, Hong-Jian Zhu, Gary P Anderson, David M Tarlinton, Margaret L Hibbs.   

Abstract

Regulatory T cells (Tregs) are a subset of T lymphocytes that are responsible for suppressing the function of other immune cells, and preventing potentially harmful autoimmune responses. Studies in autoimmune-prone mice and human autoimmune diseases have shown reduced Treg number or function as a causative factor for the apparent loss of tolerance that contributes to disease. We have found that Lyn-deficient mice, which develop high titers of autoantibodies with age, have a perturbed Treg compartment. Contrary to what has been observed in some strains of autoimmune-prone mice, aged Lyn-deficient mice have increased numbers of Tregs. This expansion occurs in the presence of elevated serum IL-2 and diminished TGF-beta. Despite expansion of the Treg compartment, Lyn-deficient mice succumb at approximately 1 year of age due to immune complex-mediated glomerulonephritis. We have shown that Lyn is not expressed in Tregs or indeed in any T cell subset, suggesting that the expansion and apparent functional deficiency in Tregs in Lyn-deficient mice is due to extrinsic factors rather than an intrinsic Treg defect. Indeed, using an in vivo colitis model, we have shown that Lyn-deficient Tregs can suppress inflammation. These results suggest that Tregs are expanding in Lyn-deficient mice in an effort to control the autoimmune disease but are simply overwhelmed by the disease process. This study highlights the role of the inflammatory setting in autoimmune disease and its consideration when contemplating the use of Tregs as an autoimmune therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620313     DOI: 10.4049/jimmunol.0804346

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Lyn mitigates mouse airway remodeling by downregulating the TGF-β3 isoform in house dust mite models.

Authors:  Guoping Li; John Fox; Zhigang Liu; Jun Liu; George F Gao; Yang Jin; Hongwei Gao; Min Wu
Journal:  J Immunol       Date:  2013-10-14       Impact factor: 5.422

2.  IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in lyn-/- mice.

Authors:  Toni Gutierrez; Jessica M Mayeux; Sterling B Ortega; Nitin J Karandikar; Quan-Zhen Li; Dinesh Rakheja; Xin J Zhou; Anne B Satterthwaite
Journal:  Eur J Immunol       Date:  2012-12-18       Impact factor: 5.532

3.  Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Authors:  Matthew B Dong; Guangchuan Wang; Ryan D Chow; Lupeng Ye; Lvyun Zhu; Xiaoyun Dai; Jonathan J Park; Hyunu R Kim; Youssef Errami; Christopher D Guzman; Xiaoyu Zhou; Krista Y Chen; Paul A Renauer; Yaying Du; Johanna Shen; Stanley Z Lam; Jingjia J Zhou; Donald R Lannin; Roy S Herbst; Sidi Chen
Journal:  Cell       Date:  2019-08-22       Impact factor: 41.582

4.  B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice.

Authors:  Patrizia Scapini; Chrystelle Lamagna; Yongmei Hu; Karim Lee; Qizhi Tang; Anthony L DeFranco; Clifford A Lowell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-12       Impact factor: 11.205

5.  B cell-specific loss of Lyn kinase leads to autoimmunity.

Authors:  Chrystelle Lamagna; Yongmei Hu; Anthony L DeFranco; Clifford A Lowell
Journal:  J Immunol       Date:  2013-12-27       Impact factor: 5.422

6.  Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice.

Authors:  Zhaolin Hua; Andrew J Gross; Chrystelle Lamagna; Natalia Ramos-Hernández; Patrizia Scapini; Ming Ji; Haitao Shao; Clifford A Lowell; Baidong Hou; Anthony L DeFranco
Journal:  J Immunol       Date:  2013-12-30       Impact factor: 5.422

Review 7.  Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy.

Authors:  Kamalakannan Rajasekaran; Matthew J Riese; Sridhar Rao; Li Wang; Monica S Thakar; Charles L Sentman; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2016-05-12       Impact factor: 7.561

Review 8.  Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.

Authors:  Timothy A Gottschalk; Evelyn Tsantikos; Margaret L Hibbs
Journal:  Front Immunol       Date:  2015-10-28       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.